NEW YORK (GenomeWeb News) – PGXL Labs today announced a partnership for the use of AutoGenomics' Infiniti Analyzer for several personal medicine applications.
PGXL plans to use the Infiniti Warfarin assay and the CYP450 assay, both of which have been cleared by the US Food and Drug Administration, as well as the Infiniti KRAS-BRAF test, it said.
AutoGenomics' Infiniti Analyzer is a microarray-based molecular diagnostics platform for measuring multiple signals from clinical samples.
Financial and other terms of the deal were not disclosed.
Based in Louisville, Ky., PGXL said it was the first laboratory in the US to be CLIA-certified specifically to conduct pharmacogenomic tests and developed one of the first commercially available CYP2C9/VKORC1 tests for accurate anticoagulant dosing. It also offers contract research organization services to drug and medical equipment manufacturers.